spironolactone has been researched along with Liver Dysfunction in 42 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among 459 patients with hepatic edema enrolled in a retrospective, multicenter collaborative study, we analyzed 407 patients who received tolvaptan." | 7.96 | Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. ( Abe, H; Arai, T; Atsukawa, M; Chuma, M; Fukunishi, S; Hattori, N; Hiraoka, A; Iio, E; Ikegami, T; Itokawa, N; Iwakiri, K; Iwasa, M; Kato, K; Kondo, C; Kumada, T; Michitaka, K; Nakagawa-Iwashita, A; Nozaki, A; Okubo, H; Okubo, T; Senoh, T; Tada, T; Takaguchi, K; Takei, Y; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsutsui, A; Uojima, H; Watanabe, T; Yokohama, K; Yoshida, Y, 2020) |
| "Ten patients with ascites due to chronic liver disease were treated with spironolactone as the sole diuretic in doses of 300 to 600 mg daily." | 7.66 | Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. ( Campra, JL; Reynolds, TB, 1978) |
| "The elimination half-life (T1/2) of canrenone, the principal unconjugated metabolite of spironolactone, was 59 h (range 32-105 h) in 5 patients with chronic liver disease and 37 h (range 19-48 h ) in 7 patients withcongestive heart failure." | 7.65 | Elimination of canrenone in congestive heart failure and chronic liver disease. ( Branch, R; Jackson, L; Levine, D; Ramsay, L, 1977) |
| "Among 459 patients with hepatic edema enrolled in a retrospective, multicenter collaborative study, we analyzed 407 patients who received tolvaptan." | 3.96 | Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. ( Abe, H; Arai, T; Atsukawa, M; Chuma, M; Fukunishi, S; Hattori, N; Hiraoka, A; Iio, E; Ikegami, T; Itokawa, N; Iwakiri, K; Iwasa, M; Kato, K; Kondo, C; Kumada, T; Michitaka, K; Nakagawa-Iwashita, A; Nozaki, A; Okubo, H; Okubo, T; Senoh, T; Tada, T; Takaguchi, K; Takei, Y; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsutsui, A; Uojima, H; Watanabe, T; Yokohama, K; Yoshida, Y, 2020) |
| "Ten patients with ascites due to chronic liver disease were treated with spironolactone as the sole diuretic in doses of 300 to 600 mg daily." | 3.66 | Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. ( Campra, JL; Reynolds, TB, 1978) |
| "In 5 healthy subjects and in 5 patients with decompensated liver diseases, the concentrations of cortisol, canrenone and canrenoate-K were determined after single doses and after a long-term treatment with spironolactone." | 3.66 | Non-interaction of spironolactone medication and cortisol metabolism in man. ( Abshagen, U; L'age, M; Spörl, S, 1978) |
| "The elimination half-life (T1/2) of canrenone, the principal unconjugated metabolite of spironolactone, was 59 h (range 32-105 h) in 5 patients with chronic liver disease and 37 h (range 19-48 h ) in 7 patients withcongestive heart failure." | 3.65 | Elimination of canrenone in congestive heart failure and chronic liver disease. ( Branch, R; Jackson, L; Levine, D; Ramsay, L, 1977) |
| "In 8 out of 20 patients with chronic liver disease ascites was controlled with metolazone, 10 required additional amiloride or spironolactone to achieve control, and 2 were resistant to all diuretic therapy." | 3.65 | Use of metolazone in the treatment of ascites due to liver disease. ( Hillenbrand, P; Sherlock, S, 1971) |
| "The mean (95% confidence limits) relative bioavailability for SP-COMP (compared with ALD) from steady state serum concentrations of canrenone, 6beta-hydroxyl 7alpha-thiomethyl spironolactone and 7alpha-thiomethyl spironolactone was 310." | 2.68 | Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex. ( Abosehmah-Albidy, AZ; Chrystyn, H; Losowsky, MS; Wong, V; York, P, 1997) |
| "Treatment with spironolactone (200 mg daily for one week in 9 subjects) did not change the steroid binding capacity of human serum." | 1.26 | [Binding capacity of sex hormone binding globulin and corticosteroid binding globulin in serum of male patients with liver cirrhosis (author's transl)]. ( Breuer, H; Kaulhausen, H; Lafosse, M; Rohner, HG; Siedek, M, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (85.71) | 18.7374 |
| 1990's | 5 (11.90) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Atsukawa, M | 1 |
| Tsubota, A | 1 |
| Takaguchi, K | 1 |
| Toyoda, H | 1 |
| Iwasa, M | 1 |
| Ikegami, T | 1 |
| Chuma, M | 1 |
| Nozaki, A | 1 |
| Uojima, H | 1 |
| Hiraoka, A | 1 |
| Fukunishi, S | 1 |
| Yokohama, K | 1 |
| Tada, T | 1 |
| Kato, K | 1 |
| Abe, H | 1 |
| Tani, J | 1 |
| Okubo, H | 1 |
| Watanabe, T | 1 |
| Hattori, N | 1 |
| Tsutsui, A | 1 |
| Senoh, T | 1 |
| Yoshida, Y | 1 |
| Okubo, T | 1 |
| Itokawa, N | 1 |
| Nakagawa-Iwashita, A | 1 |
| Kondo, C | 1 |
| Arai, T | 1 |
| Michitaka, K | 1 |
| Iio, E | 1 |
| Kumada, T | 1 |
| Tanaka, Y | 1 |
| Takei, Y | 1 |
| Iwakiri, K | 1 |
| LINTRUP, J | 1 |
| FRIIS, T | 1 |
| NISSEN, NI | 1 |
| SJOBERG, WE | 1 |
| KREISLE, JE | 1 |
| STERNBERG, MS | 1 |
| HAGEDORN, CW | 1 |
| KALSER, MH | 1 |
| FLETCHER, CB | 1 |
| EAKIN, EL | 1 |
| ROTHMAN, PE | 1 |
| PERISIC, V | 1 |
| KONECNI, J | 1 |
| BANICEVIC, B | 1 |
| HENLEY, KS | 1 |
| STREETEN, DH | 1 |
| POLLARD, HM | 1 |
| PUPITA, F | 1 |
| DE MARTINIS, C | 1 |
| Dorner, M | 1 |
| Frey, G | 1 |
| Siegers, CP | 1 |
| Klaassen, CD | 1 |
| Kuntz, E | 3 |
| Kaulhausen, H | 1 |
| Rohner, HG | 1 |
| Siedek, M | 1 |
| Lafosse, M | 1 |
| Breuer, H | 1 |
| Epping, J | 1 |
| Fuchshofen, M | 1 |
| Richter, E | 1 |
| Jolobe, OM | 1 |
| Abosehmah-Albidy, AZ | 1 |
| York, P | 1 |
| Wong, V | 1 |
| Losowsky, MS | 1 |
| Chrystyn, H | 1 |
| Campra, JL | 1 |
| Reynolds, TB | 2 |
| Genes, SG | 1 |
| Bossone, CM | 1 |
| Abshagen, U | 2 |
| Spörl, S | 1 |
| L'age, M | 1 |
| Jackson, L | 1 |
| Branch, R | 1 |
| Levine, D | 1 |
| Ramsay, L | 1 |
| Rennekamp, H | 1 |
| Luszpinski, G | 1 |
| Loginov, AS | 1 |
| Danks, DM | 1 |
| Potter, C | 1 |
| Willis, D | 1 |
| Sharp, HL | 1 |
| Scharzenberg, SJ | 1 |
| Schölmerich, J | 1 |
| Iacona, A | 1 |
| Rossetti, A | 1 |
| Filingeri, V | 1 |
| Orsini, D | 1 |
| Cesarini, A | 1 |
| Cervelli, V | 1 |
| Adorno, D | 1 |
| Casciani, CU | 1 |
| Morris, RG | 1 |
| Frewin, DB | 1 |
| Taylor, WB | 1 |
| Glistak, ML | 1 |
| Lehmann, DR | 1 |
| Pockros, PJ | 1 |
| Lant, A | 1 |
| Ilinich, VK | 1 |
| Plastun, FF | 1 |
| Lazar, G | 1 |
| Szabo, S | 1 |
| Husztik, E | 1 |
| Wilkinson, SP | 1 |
| Arroyo, V | 1 |
| Williams, R | 1 |
| Blendis, LM | 1 |
| Wildhirt, E | 1 |
| Sadée, W | 1 |
| Schröder, R | 1 |
| von Leitner, E | 1 |
| Dagcioglu, M | 1 |
| Reubi, FC | 1 |
| Larcan, A | 1 |
| Calamai, M | 1 |
| Jacob, F | 1 |
| Hillenbrand, P | 1 |
| Sherlock, S | 1 |
| Gentili, G | 1 |
| Liberti, R | 1 |
| Steigmann, F | 1 |
| Oz, R | 1 |
| Dubin, A | 1 |
6 reviews available for spironolactone and Liver Dysfunction
| Article | Year |
|---|---|
[The importance of the biliary excretion of drugs in the human].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bile; Biological Transport; Cardiac Glycosides; Contra | 1983 |
Strategies in the treatment of ascites.
Topics: Ascites; Diet, Sodium-Restricted; Drainage; Humans; Liver Diseases; Peritoneovenous Shunt; Plasma Su | 1991 |
Diuretics. Clinical pharmacology and therapeutic use (Part II).
Topics: Amiloride; Canrenoic Acid; Diuretics; Diuretics, Osmotic; Drug Interactions; Hearing Disorders; Hear | 1985 |
[Hepatogenous (secondary) aldosteronism (author's transl)].
Topics: Aldosterone; Angiotensin II; Chronic Disease; Esophageal and Gastric Varices; Hepatitis; Hepatitis A | 1974 |
[Treatment of acute hepatic insufficiency (a survey of the literature)].
Topics: Acute Disease; Adenosine Triphosphate; Arginine; Chemical and Drug Induced Liver Injury; Exchange Tr | 1972 |
Combination diuretic drug therapy.
Topics: Amiloride; Benzothiadiazines; Diet; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Furosemid | 1971 |
1 trial available for spironolactone and Liver Dysfunction
| Article | Year |
|---|---|
Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
Topics: beta-Cyclodextrins; Biological Availability; Canrenone; Chronic Disease; Cross-Over Studies; Cyclode | 1997 |
35 other studies available for spironolactone and Liver Dysfunction
| Article | Year |
|---|---|
Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
Topics: Adult; Aged; Aged, 80 and over; Diuretics; Drug Therapy, Combination; Edema; Female; Furosemide; Hum | 2020 |
[Diuretic action of chlorothiazide and spironolactone in edema of cardiac and hepatic origin].
Topics: Chlorothiazide; Diuretics; Edema; Heart Failure; Liver Diseases; Spironolactone | 1963 |
Hyperkalemia and sudden death during Spironolactone (Aldactone) therapy.
Topics: Death, Sudden; Humans; Hyperkalemia; Kidney Diseases; Liver Diseases; Spironolactone | 1962 |
THE USE OF SPIRONOLACTONE AND LARGE DOSES OF STEROIDS IN THE TREATMENT OF ASCITES OF LIVER DISEASE.
Topics: Adrenal Cortex Hormones; Ascites; Chlorothiazide; Diuresis; Hepatic Encephalopathy; Humans; Hyponatr | 1963 |
FETAL ASCITES--LIVER GIANT-CELL TRANSFORMATION. REPORT OF A CASE WITH RECOVERY.
Topics: Ascites; Biopsy; Drainage; Exchange Transfusion, Whole Blood; Fetal Diseases; Humans; Hydrochlorothi | 1964 |
[EFFECT OF A SPIRONOLACTONE ALDOSTERONE INHIBITOR AND CHLOROTHIAZIDE ON WATER AND ELECTROLYTE EXCRETION IN LIVER DISEASES].
Topics: Aldosterone; Biomedical Research; Body Fluids; Chlorothiazide; Electrolytes; Liver Diseases; Mineral | 1964 |
Hyperaldo-steronism in liver disease. The treatment of refractory ascites by adrenalectomy and by the administration of spirolactones.
Topics: Adrenalectomy; Aldosterone; Ascites; Humans; Lactones; Liver Diseases; Spironolactone | 1960 |
[On the therapy of edemas caused by liver disease. Changes of water-salt metabolism and of the urinary corticosteroid picture in cirrhotics treated with prednisone, spirolactone and methopyrone].
Topics: Adrenal Cortex Hormones; Ascites; Edema; Humans; Liver Cirrhosis; Liver Diseases; Prednisone; Spiron | 1961 |
[Saluretics in liver diseases].
Topics: Ammonium Chloride; Ascites; Capillary Permeability; Diuretics; Humans; Hypertension, Portal; Hypopro | 1966 |
[Disorders of water and electrolyte equilibrium in liver diseases. Part 3: therapy (author's transl)].
Topics: Ascites; Benzothiadiazines; Canrenoic Acid; Diuretics; Humans; Hyperaldosteronism; Liver Diseases; S | 1982 |
[Binding capacity of sex hormone binding globulin and corticosteroid binding globulin in serum of male patients with liver cirrhosis (author's transl)].
Topics: Adult; Aged; Blood Proteins; Cholinesterases; Electrophoresis, Agar Gel; Factor V; Factor VII; Human | 1980 |
[Enterohepatic circulation in liver diseases].
Topics: Animals; Barbiturates; Bile Acids and Salts; Biotransformation; Bisacodyl; Chloramphenicol; Cholesta | 1980 |
Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis.
Topics: Aged; Captopril; Diuresis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furo | 1993 |
Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites.
Topics: Adult; Ascites; Blood Urea Nitrogen; Creatinine; Drug Evaluation; Female; Hepatitis, Alcoholic; Huma | 1978 |
[Corticosteroids and the liver].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Animals; Biotransformation; Diabetes Mellitus, Experimental | 1977 |
The liver: a pharmacologic perspective.
Topics: Acetaldehyde; Alcoholism; Chemical and Drug Induced Liver Injury; Diuretics; Drug-Related Side Effec | 1977 |
Management of hepatic ascites.
Topics: Ascites; Diuresis; Drainage; Humans; Hypokalemia; Liver Diseases; Spironolactone | 1978 |
Non-interaction of spironolactone medication and cortisol metabolism in man.
Topics: Canrenoic Acid; Canrenone; Drug Interactions; Humans; Hydrocortisone; Liver Diseases; Spironolactone | 1978 |
Elimination of canrenone in congestive heart failure and chronic liver disease.
Topics: Aged; Canrenone; Chronic Disease; Creatinine; Female; Half-Life; Heart Failure; Humans; Liver Diseas | 1977 |
Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment.
Topics: Adult; Chemical and Drug Induced Liver Injury; Half-Life; Humans; Kinetics; Liver Cirrhosis; Liver D | 1977 |
[Treatment of chronic diseases of the liver].
Topics: Adrenal Cortex Hormones; Chronic Disease; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Phenob | 1977 |
[Edematous hepatitis: a special form of acute virus hepatitis with secondary aldosteronism (author's transl)].
Topics: Adult; Aldosterone; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Edema; Female; | 1975 |
Letter: Diuretic therapy in infants and children.
Topics: Child; Furosemide; Humans; Infant; Liver Diseases; Spironolactone | 1976 |
Primary and secondary amenorrhea associated with spironolactone therapy in chronic liver disease.
Topics: Adolescent; Adult; Amenorrhea; Cholestasis; Chronic Disease; Female; Humans; Hypertension, Portal; H | 1992 |
Reduced nephrotoxicity and hepatoxicity in cyclosporin A therapy by enalapril and spironolactone in rats.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cyclosporine; Drug Therapy, Combination; Enalapril; | 1991 |
The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays.
Topics: Aged; Aged, 80 and over; Digoxin; Female; Humans; Immunoassay; Kidney Diseases; Liver Diseases; Male | 1988 |
Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema.
Topics: Amiloride; Ascites; Body Weight; Chronic Disease; Diuresis; Edema; Electrolytes; Furosemide; Humans; | 1986 |
The experimental production of hemorrhagic lesions in the rat adrenal, liver and lung by basic polyglutamic acid derivatives.
Topics: Adrenal Gland Diseases; Adrenal Glands; Animals; Chemical and Drug Induced Liver Injury; Ethylestren | 1972 |
Letter: Ascites and oedema in liver disease.
Topics: Ascites; Edema; Humans; Kidney; Liver Diseases; Spironolactone | 1973 |
[Aldosteronism in liver diseases].
Topics: Acute Disease; Aldosterone; Chronic Disease; Humans; Hyperaldosteronism; Liver Diseases; Spironolact | 1974 |
Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
Topics: Adult; Aged; Carboxylic Acids; Female; Fluorometry; Half-Life; Heart Failure; Humans; Ketosteroids; | 1974 |
[Severe kaliopenia and electrolytic gradient disturbances in medico-surgical resuscitation. Value of a spironolactone with antialdosterone and catatoxic effect].
Topics: Brain Edema; Cardiac Surgical Procedures; Cardiovascular Diseases; Extracorporeal Circulation; Human | 1971 |
Use of metolazone in the treatment of ascites due to liver disease.
Topics: Adult; Ascites; Chlorides; Chronic Disease; Diuretics; Female; Hepatic Encephalopathy; Humans; Hypok | 1971 |
[Clinical study of the use of "Spirolang" 50].
Topics: Adult; Aged; Ascites; Chronic Disease; Digitalis Glycosides; Diuresis; Electrolytes; Ethacrynic Acid | 1971 |
Newer diuretics in the treatment of cardiac or hepatic disease in elderly patients.
Topics: Ascites; Benzothiadiazines; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cardiovascular Diseases | 1966 |